Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody

详细信息    查看全文

• 作者：Justyna M. Meissner^a ; ^b ; ¹ ; Monika Toporkiewicz^a ; ¹ ; Aleksander Czogalla^a ; Lucyna Matusewicz^a ; Kazimierz Kuliczkowski^c ; Aleksander F. Sikorski^a ; ^{afsbc@ibmb.uni.wroc.pl" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Targeted liposomes ; Antisense nucleotide therapy ; Cationic lipids ; Polyethylenimine ; Bcl-2 protein ; BCL2 gene ; B-cell malignancies
• 刊名：Journal of Controlled Release
• 出版年：2015
• 出版时间：28 December 2015
• 年：2015
• 卷：220
• 期：part_PA
• 页码：515-528
• 全文大小：1420 K

文摘

Antisense gene therapy using molecules such as antisense oligodeoxynucleotides, siRNA or miRNA is a very promising strategy for the treatment of neoplastic diseases. It can be combined with other treatment strategies to enhance therapeutic effect. In acute leukemias, overexpression of the antiapoptotic gene BCL2 is observed in more than 70% of cases. Therefore, reduction of the Bcl-2 protein level could, in itself, prevent the development of cancer or could possibly help sensitize cancer cells to apoptosis inducers.

The main objective of our work is to develop therapeutic liposome formulations characterized by high transfection efficiency, stability in the presence of serum, as well as specificity and toxicity for target (leukemic) cells. Each of our liposomal formulations consists of a core composed of antisense oligonucleotides complexed by either cationic lipid, DOTAP, or a synthetic polycation, polyethyleneimine, encapsulated within liposomes modified with polyethylenoglycol. In addition, the liposomal shells are enriched with covalently-bound antibodies recognizing a well characterized bio-marker, CD20, exposed on the surface of leukemia cells. The resulting immunoliposomes selectively and effectively reduced the expression of BCL2 in target cells. Model animal experiments carried out on mice-engrafted tumors expressing the specific marker showed high efficiency of the liposome formulations against specific tumor development. In conclusion, we show that lipid formulations based on a polyplex or lipoplex backbone additionally equipped with antibodies are promising non-viral vectors for specific oligonucleotide transfer into human tumor cells.